Campaign Introduces “Phil the Pill” as New Character Personifying How Big
Pharma Tries to Disguise the Truth





 



CSRxP LAUNCHES ADVERTISING CAMPAIGN HIGHLIGHTING BIG PHARMA’S EGREGIOUS
PRACTICES THAT ARE ROOT CAUSE OF HIGH PRESCRIPTION DRUG PRICES, HEALTH CARE
INFLATION

Campaign Introduces “Phil the Pill” as New Character Personifying How Big
Pharma Tries to Disguise the Truth



Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) announced
the launch of a new advertising campaign on Thursday, highlighting how Big
Pharma’s patent abuse tactics and egregious pricing practices are the root
cause of high prescription drug costs, and a major driver of health care
inflation, in America. The new ad introduces “Phil the Pill,” a new character
who highlights the many ways Big Pharma tries to “disguise the truth” of brand
name manufacturers’ role in making prescription drugs and health care
unaffordable for too many Americans — by pointing fingers at others and relying
on debunked innovation rhetoric.



“Big Pharma loves to point fingers at others and rehash debunked arguments on
innovation in order to avoid accountability for brand name manufacturers,
oppose solutions that would lower drug prices for American patients and
maintain the pharmaceutical industry’s business-as-usual approach to
price-gouging,” said CSRxP executive director Lauren Aronson. “CSRxP’s new
campaign showcases the absurdity of Big Pharma’s blame game, underscoring that
brand name drug companies’ egregious pricing practices and anti-competitive
tactics are the root cause of high prescription drug prices and a major driver
of health care inflation in America. Delivering more affordable health care for
the American people must mean holding Big Pharma accountable to lower
prescription drug prices.”



Watch CSRxP’s new ad “Master of Disguise” HERE
<[link removed]>.



The campaign follows the release of a recent CSRxP analysis
<[link removed]>
revealing that the pharmaceutical industry continues to post profit margins10
times higherthan other sectors of the prescription drug supply chain. The
updated findings confirm that Big Pharma’s egregious pricing and
anti-competitive playbook continue to drive blockbuster profits at the expense
of patients.



Read more on CSRxP’s new margin analysis HERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to lower drug prices by
holding Big Pharma accountable for anti-competitive abuse of the U.S. patent
systemHERE
<[link removed]>
.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>